NanoSphere Health Sciences Inc (NSHS.X) AI Stock Analysis

NanoSphere Health Sciences Inc

(CNQX:NSHS.X)

Select Model

Rating:40Underperform

Price Target:CAD 0.02▼(-4.00% Downside)

Action:downgraded

Date:10/24/26

Financial performance is the primary driver but remains weak due to lack of revenue and negative equity; technical momentum is soft and valuation metrics are unattractive given persistent losses.

Positive Factors

Narrowing Cash BurnA declining burn rate is a constructive operational trend because it may extend available resources and reduce the pace of financing needs. However, the company remains cash-flow negative, so this improvement supports resilience rather than demonstrating self-funded growth or financial independence.

Negative Factors

No Revenue BaseThe absence of reported revenue indicates that the company remains pre-commercial or inactive on the top line, leaving no demonstrated customer demand or operating scale. Without recurring sales, future growth and any path toward sustainable profitability remain highly uncertain.

NanoSphere Health Sciences Inc (NSHS.X) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 205.50K
Dividend Yield: ―
Average Volume (3M): 4,787
Price to Earnings (P/E): -1.8
Beta (1Y): -2.98
Revenue Growth: ―
EPS Growth: -132.14%
Country: Canada
Employees: 5
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

NanoSphere Health Sciences Inc Business Overview & Revenue Model

Company Description

NanoSphere Health Sciences Inc. is a nano-biotechnology enterprise operating in the United States and Canada, specializing in the provision of biologically active compounds. The company's primary offering is the NanoSphere Delivery System, an innovat...

NanoSphere Health Sciences Inc Financial Statement Overview

Summary

Pre-revenue biotech with zero revenue, negative equity, and ongoing cash burn; however, net losses have narrowed substantially and free cash flow burn rate has improved.

Income Statement

15Very Negative

Balance Sheet

10Very Negative

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
EBITDA	-213.44K	-181.91K	-251.59K	-319.60K	-286.00K	-341.00K
Net Income	-83.07K	-86.27K	―	-228.13K	-282.00K	-356.00K
Balance Sheet
Total Assets	16.81K	16.81K	13.59K	17.97K	60.05K	132.51K
Cash, Cash Equivalents and Short-Term Investments	1,882	1,882	2,022	9,316	55.01K	130.76K
Total Debt	57.14K	57.14K	30.71K	0	0	0
Total Liabilities	1.37M	1.37M	1.23M	1.57M	1.37M	1.21M
Stockholders Equity	-1.35M	-1.35M	-1.22M	-1.56M	-1.31M	-1.08M
Cash Flow
Free Cash Flow	-24.33K	-23.38K	-35.92K	-53.70K	-67.66K	-64.68K
Operating Cash Flow	-24.33K	-23.38K	-35.92K	-53.70K	-67.66K	-64.68K
Investing Cash Flow	0	0	0	0	0	0
Financing Cash Flow	26.57K	27.00K	28.83K	0	0	182.43K

NanoSphere Health Sciences Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:NSHS.X against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:NSHS.X	40Underperform	CAD 256.88K	-1.76	6.14%	―	―	-132.14%
TSE:VXL	37Underperform	CAD 398.40K	1.00	34.52%	―	―	―
TSE:CHGX	24Underperform	CAD 415.65K	-0.23	19.40%	―	―	―

* Healthcare Sector Average

Performance Comparison

TSE:NSHS.X and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:NSHS.X	Nanosphere Health Sciences	0.03	-0.00	-16.67%
TSE:WESA.X	Wesana Health Holdings Inc	0.01	0.00	0.00%
TSE:ABRT	Albert Labs International Corp.	0.01	0.00	0.00%
TSE:VXL	Vaxil Bio	0.10	-0.07	-41.18%
TSE:CHGX	Chitogenx Inc.	0.01	0.00	0.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026

NanoSphere Health Sciences Inc AI Stock Analysis